Adicet Bio (ACET) Q3 2026 earnings summary

Executive summary

• Prula-cel Phase 1 data showed durable clinical responses and a favorable safety profile in SLE patients with or without LN, supporting pivotal LN study startup.

• ADI-212 received FDA IND clearance and Fast Track Designation for mCRPC; first in vivo CAR-T candidate is planned to enter the clinic in 2H 2027.

Financial highlights

• Q3 2026 R&D expense was $15.6M vs. $22.9M YoY; G&A was $4.2M vs. $5.1M.

• Q3 operating expenses were $19.8M vs. $28.0M YoY; net loss was $18.9M vs. $26.9M, including $2.7M of noncash charges.

• 9M 2026 operating expenses were $63.7M vs. $90.2M; net loss was $60.5M vs. $86.3M YoY.

Outlook and guidance

• Cash, cash equivalents and short-term investments of $100.9M at Sept. 30, 2026, are expected to fund operating expenses into 2H 2027.

• FDA discussion on potential pivotal expansion of prula-cel to lupus without nephritis is planned for 4Q 2026; regulatory update and ~22-patient 12-month follow-up data are expected in 1Q 2027.

• Prula-cel systemic sclerosis Phase 1 data are expected in 2Q 2027; ADI-212 mCRPC enrollment is anticipated to begin in 1Q 2027.